News

Grenova Secures New Investment; Appoints Life Sciences Veteran to the Board

Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova’s board, and the successful completion of a new round of growth equity capital. These developments support Grenova’s strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. 

Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company’s future. 

“I am honored to join Grenova at such an exciting time in the company’s journey,” said Hull. “Grenova is revolutionizing the way laboratories think about and use plastics—transforming single-use mindsets into sustainable, reusable solutions. I look forward to working closely with this talented team to continue driving meaningful change.” 

The addition to Grenova’s team is complemented by a new round of equity capital. The funding will be used to enhance Grenova’s automation portfolio, expand R&D capabilities, and grow the team to meet rising demand across global markets. The financing was led by Grenova investors, Peloton Equity and Hamilton Lane’s (Nasdaq: HLNE) Impact Fund II, along with other existing investors,  

“This investment affirms confidence in our vision and the market’s urgency to reduce plastic waste,” said Katherine Marrs, CEO of Grenova. “With this capital and Ted Hull on the board, we’re positioned to accelerate our mission to scale sustainable lab practices.” 

“We are excited to continue supporting Grenova’s growth,” said Ted Lundberg, Peloton Equity Managing Partner and Grenova’s Chairman. “We have worked with Ted Hull over the past 20 years and are thrilled to have him join Grenova. Ted brings a powerful blend of vision and experience that will help Grenova press its advantage as a category leader.” 

Backed by experienced leadership, a unique and patent protected product suite, strong investor confidence, and a clear vision, Grenova is working revolutionize laboratories worldwide. 

 

Read more here.

Recent News

12/02/2025

New Report Highlights State and Regional Strategies Powering U.S. Biotech

The Biotechnology Innovation Organization (BIO), in partnership with the Council of State Bioscience Associations (CSBA), released today its latest biennial report on best practices in bioscience economic development initiatives: The U.S. Bioscience Industry: A Powerful Engine for State Economies. The report details the diverse strategies states, cities, and municipalities are using to strengthen the bioscience

11/25/2025

ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Howard Berman, Ph.D., as Executive Chairman of the ReAlta Life Sciences Board of Directors, effective immediately. “We are delighted

11/23/2025

ATCC Welcomes National Security Commission on Emerging Biotechnology for the Capital Region Stop of the Biotech Across America Roadshow

ATCC, the world’s premier private, non-profit biological resources and standards organization, hosted an event today, Empowering the Future of Biotechnology Through Trusted Science, with the National Security Commission on Emerging Biotechnology (NSCEB) at its headquarters in Manassas, Virginia as part of the NSCEB’s “Biotech Across America” roadshow. The NSCEB met with ATCC leaders and key